Relay Therapeutics, Inc.

NasdaqGM:RLAY Stok Raporu

Piyasa değeri: US$958.5m

Relay Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Relay Therapeutics CEO'su Sanjiv Patel, Mar2017 tarihinde atandı, in görev süresi 7.58 yıldır. in toplam yıllık tazminatı $ 19.77M olup, şirket hissesi ve opsiyonları dahil olmak üzere 3.4% maaş ve 96.6% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.84% ine doğrudan sahiptir ve bu hisseler $ 8.06M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 6.5 yıl ve 5.2 yıldır.

Anahtar bilgiler

Sanjiv Patel

İcra Kurulu Başkanı

US$19.8m

Toplam tazminat

CEO maaş yüzdesi3.4%
CEO görev süresi7.6yrs
CEO sahipliği0.8%
Yönetim ortalama görev süresi6.5yrs
Yönetim Kurulu ortalama görev süresi5.2yrs

Son yönetim güncellemeleri

Recent updates

Relay Therapeutics' RLY-2608 Shows Promise For Breast Cancer With PI3Kα Mutations

Sep 11

Here's Why We're Not Too Worried About Relay Therapeutics' (NASDAQ:RLAY) Cash Burn Situation

Aug 03
Here's Why We're Not Too Worried About Relay Therapeutics' (NASDAQ:RLAY) Cash Burn Situation

Relay Therapeutics, Inc. (NASDAQ:RLAY) Analysts Just Trimmed Their Revenue Forecasts By 12%

Apr 17
Relay Therapeutics, Inc. (NASDAQ:RLAY) Analysts Just Trimmed Their Revenue Forecasts By 12%

Relay Therapeutics: Platform More Important Than Programs

Mar 13

Relay Therapeutics: Tapping Into An Unmet Need At A High Price Tag

Feb 13

Analyst Forecasts Just Became More Bearish On Relay Therapeutics, Inc. (NASDAQ:RLAY)

Jan 21
Analyst Forecasts Just Became More Bearish On Relay Therapeutics, Inc. (NASDAQ:RLAY)

We Think Relay Therapeutics (NASDAQ:RLAY) Can Afford To Drive Business Growth

Nov 14
We Think Relay Therapeutics (NASDAQ:RLAY) Can Afford To Drive Business Growth

Will Relay Therapeutics (NASDAQ:RLAY) Spend Its Cash Wisely?

Jun 08
Will Relay Therapeutics (NASDAQ:RLAY) Spend Its Cash Wisely?

Is Relay Therapeutics (NASDAQ:RLAY) In A Good Position To Invest In Growth?

Feb 22
Is Relay Therapeutics (NASDAQ:RLAY) In A Good Position To Invest In Growth?

Is Relay Therapeutics (NASDAQ:RLAY) In A Good Position To Invest In Growth?

Oct 23
Is Relay Therapeutics (NASDAQ:RLAY) In A Good Position To Invest In Growth?

Relay set to Equal Weight at Barclays; says fairly valued ahead of catalysts

Sep 30

Relay Therapeutics: Bile Duct Cancer Approval Shot Validates Pricey Platform

Sep 18

Why did Relay Therapeutics stock drop today?

Sep 09

Estimating The Fair Value Of Relay Therapeutics, Inc. (NASDAQ:RLAY)

Jan 02
Estimating The Fair Value Of Relay Therapeutics, Inc. (NASDAQ:RLAY)

Relay Therapeutics, Inc. (NASDAQ:RLAY) Analysts Are Reducing Their Forecasts For This Year

Aug 17
Relay Therapeutics, Inc. (NASDAQ:RLAY) Analysts Are Reducing Their Forecasts For This Year

CEO Tazminat Analizi

Sanjiv Patel'un ücretlendirmesi Relay Therapeutics'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2024n/an/a

-US$323m

Mar 31 2024n/an/a

-US$329m

Dec 31 2023US$20mUS$674k

-US$342m

Sep 30 2023n/an/a

-US$326m

Jun 30 2023n/an/a

-US$344m

Mar 31 2023n/an/a

-US$323m

Dec 31 2022US$8mUS$642k

-US$291m

Sep 30 2022n/an/a

-US$290m

Jun 30 2022n/an/a

-US$267m

Mar 31 2022n/an/a

-US$384m

Dec 31 2021US$9mUS$603k

-US$364m

Sep 30 2021n/an/a

-US$261m

Jun 30 2021n/an/a

-US$414m

Mar 31 2021n/an/a

-US$247m

Dec 31 2020US$4mUS$585k

-US$230m

Sep 30 2020n/an/a

-US$289m

Jun 30 2020n/an/a

-US$95m

Mar 31 2020n/an/a

-US$86m

Dec 31 2019US$4mUS$585k

-US$75m

Tazminat ve Piyasa: Sanjiv 'nin toplam tazminatı ($USD 19.77M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 3.21M ).

Tazminat ve Kazançlar: Sanjiv şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Sanjiv Patel (50 yo)

7.6yrs

Görev süresi

US$19,770,838

Tazminat

Dr. Sanjiv K. Patel, M.A., M.D., M.B.A., MBBS, had been an Independent Director at Prothena Corporation plc since May 18, 2021 until July 1, 2023. He serves as Independent Director of ARYA Sciences Acquisi...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Alexis Borisy
Co-Founder & Independent Chairman9.5yrsUS$581.14k0.14%
$ 1.4m
Sanjiv Patel
CEO, President & Director7.6yrsUS$19.77m0.84%
$ 8.1m
Mark Murcko
Co-Founder & Directorno dataUS$548.64k0.61%
$ 5.9m
Thomas Catinazzo
Chief Financial Officer6.5yrsUS$5.22m0.0092%
$ 88.4k
Brian Adams
Chief Legal Officer & Secretary6.6yrsUS$4.51m0.024%
$ 234.3k
Peter Rahmer
Chief Corporate Development Officerno dataUS$6.78m0.0091%
$ 86.9k
Donald Bergstrom
President of Research & Development6.5yrsUS$8.57m0.040%
$ 379.9k
Dorothee Kern
Founderno dataVeri yokVeri yok
David Shaw
Founderno dataVeri yokVeri yok
Matthew Jacobson
Founderno dataVeri yokVeri yok
Jim Watters
Chief Scientific Officerless than a yearVeri yokVeri yok
Jeanne Gray
Chief People Officerno dataVeri yokVeri yok

6.5yrs

Ortalama Görev Süresi

52yo

Ortalama Yaş

Deneyimli Yönetim: RLAY 'un yönetim ekibi deneyimli ve deneyimlidir ( 6.5 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Alexis Borisy
Co-Founder & Independent Chairman9.5yrsUS$581.14k0.14%
$ 1.4m
Sanjiv Patel
CEO, President & Director7.6yrsUS$19.77m0.84%
$ 8.1m
Mark Murcko
Co-Founder & Director8.3yrsUS$548.64k0.61%
$ 5.9m
Douglas Ingram
Independent Director5.3yrsUS$548.64k0.015%
$ 147.5k
Linda Hill
Independent Director6yrsUS$551.14k0%
$ 0
George Demetri
Member of Oncology Advisory Board4.6yrsVeri yokVeri yok
Laura Shawver
Independent Director7.6yrsUS$551.14k0.025%
$ 236.0k
Lillian Siu
Member of Oncology Advisory Board4.6yrsVeri yokVeri yok
Jamilu Rubin
Independent Director5yrsUS$558.64k0.041%
$ 396.7k
Pamela Munster
Member of Oncology Advisory Board4.6yrsVeri yokVeri yok
Trever Bivona
Member of Oncology Advisory Board4.6yrsVeri yokVeri yok
Dejan Juric
Member of Oncology Advisory Board4.6yrsVeri yokVeri yok

5.2yrs

Ortalama Görev Süresi

62.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: RLAY 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.2 yıldır).